Taiwan’s Pioneer in Genetic Diagnosis and Maternal-Fetal Medicine Provides Expertise and Support for Its Cooperation Partners

As a leader in genetic diagnosis in Taiwan, Sofiva Genomics is the first team in Asia to implement preimplantation genetic diagnosis (PGD) and offer preimplantation genetic screening (PGS). It is also the first to use next generation sequencing (NGS) for non-invasive prenatal chromosome screening, microdeletion syndrome screening, and preimplantation chromosome screening.  Moreover, Sofiva Genomics is continually dedicating efforts into cutting-edge research on rare disease, genetic disease, cancer, chronic disease, and cardiovascular disease.  It has led research into genetic screening for hereditary hearing loss, congenital central hypoventilation syndrome, and congenital cytomegalovirus infection.  With so much research efforts, it is not surprising that Sofiva Genomics was the first to publish international papers on the use of PIGF, sFIt1, and hemodynamics to predict preeclampsia. 

In addition to research, Sofiva Genomics also possesses strong product development capability with the ability to translate research findings into products and services that benefit the patients.  For example, it was one of the earliest provider to implement aCGH technology into prenatal diagnosis, developed gene screening for spinal muscular atrophy (SMA), and introduced personalized gene testing.

Sofiva Genomics has established a platform that can detect over 100 rare diseases and diagnostic methods that can detect dozens of genetic diseases. It offers comprehensive one-stop, patient-centered services that delivers only the best solutions to its patients. From initial consultation, sample preparation, analysis, to how to solve problems after seeing the report, Sofiva Genomics provides services, support, and consultation at all steps of the genetic testing/screening process.

In addition, it has signed a cooperation agreement and developed long-term collaboration strategies with illumina^®, the global leader in gene sequencing, which allows the companies to share resources and ensure that Sofiva Genomics' services remain competitive. In terms of international development, Sofiva Genomics has already established its operations in China, Hong Kong, Thailand, Malaysia, Vietnam, and Indonesia. At this year's Taiwan Healthcare+ Expo, Sofiva Genomics will focus on boosting its promotion and collaborations on maternal fetal medicine, neonatal genetic screening, and cancer and personalized genetic tests. The company will keep cultivating the ASEAN market and reach out to the Middle East countries.

(Editing by Jim Shih, Research Center for Biotechnology and Medicine Policy)

• For more information see the Taiwan Healthcare+ and 2018 Taiwan Healthcare+ Expo